Navigation Links
MS Drug Fails The Test For Treating Crohns Disease

Biogen Idec's chief executive, James Mullen is not a happy man. The Cambridge biotechnology company is not likely to receive approval from European regulators to use its drug Tysabri to treat patients with Crohn's disease, a debilitating intestinal ailment.

Results from drug trials that were included in an application to the European Medicines Agency were marked as "interesting but need more development". Now, an additional clinical trial proposed by the agency could take years and cost Biogen Idec millions of dollars, says Mullen.

Biogen Idec and Elan Corp. of Ireland have partnered on development of Tysabri since 2001. After showing promising results in testing, the drug was introduced in the United States in November 2004 to treat patients with multiple sclerosis, but was abruptly withdrawn from the market after the companies found two patients in Tysabri trials had contracted a potentially fatal brain disease. Ultimately, three patients were found to have contracted the brain disease, progressive multifocal leukoencephalopathy, or PML, and two died from it.

Yet, after impassioned testimonies from multiple sclerosis patients anxious for a chance to try Tysabri, the Food and Drug Administration permitted sales to resume, but Biogen Idec was required to take additional safety precautions, including a mandatory registry of patients receiving the drug.

In recent public statements, officials from Biogen Idec and Elan touted Tysabri's ability to induce remission in Crohn's patients. In their partnership, Biogen Idec has led trials and regulatory filings related to multiple sclerosis, and Elan has overseen the potential expansion of Tysabri as a treatment for Crohn's disease. "The data suggest that Tysabri could be an alternative biologic choice for Crohn's disease patients, says Elan.As the data continue to unfold, [Elan and Biogen Idec] will explore additional indications, as appropriate, to unmet medical needs", the company was quoted.

In a comprehensive safety review last year, the companies found two multiple sclerosis patients with PML who were also being treated with Biogen Idec's drug Avonex, another treatment for multiple sclerosis. One of those patients survived. Another patient in a Crohn's trial, who died from PML, had been treated with immunosuppressants.

This pattern, according to experts, suggests that the risks of contracting PML while using Tysabri could increase if a patient is also being given a drug that affects the immune system. If so, that raises the risks of treating Crohn's patients with Tysabri, because many have weakened immune systems.

"Against the backdrop of PML, where you have a set of patients that already get bombarded with immunosuppressants over 20 to 30 years, [Crohn's] is not the first place we'd go to develop Tysabri," states Mullen. According to him, the drug looks more promising as a treatment for Lupus and certain cancers.


'"/>




Related medicine news :

1. Alcoholism Drug Fails To Prevent Drinking Relapses
2. Tamiflu Fails To Save Two Lives
3. Himachal Pradesh Fails To Become Health Tourism Center
4. Budhias Medical Report Fails to Address Long Term Health Issues
5. "Daydreaming" Network Fails In Autism
6. 72-year-old Bachelor of Rajasthan Fails Class 10 Again!
7. Already Short Staffed And In Deficit NHS Fails To Supply Staff For IT Project
8. NHS 24 Fails To Save a Retired Nurse
9. Smartcard Legislation Fails The Privacy Test - AMA
10. Support Fails Rural Heart Patients
11. Steroid Use Fails to Boost Pregnancy Rates in Infertility Treatments
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified ... be personalized through a fitness app. The fitness app plans to fix the two major ... only offer a one size fits all type program , They don’t eliminate ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
Breaking Medicine Technology: